Literature DB >> 20564406

Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.

Chia-Yang Hsu1, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Han-Chieh Lin, Pui-Ching Lee, Che-Chuan Loong, Jen-Huey Chiang, Teh-Ia Huo, Shou-Dong Lee.   

Abstract

BACKGROUND: Selecting an appropriate staging system is crucial to predict the outcome of patients with hepatocellular carcinoma (HCC). The optimal prognostic model for HCC is under intense debate. This study investigated the prognostic ability of the 5 currently used staging systems, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Japan Integrated Scoring (JIS) system, tumor-node-metastasis (TNM), and Tokyo score, for HCC.
METHODS: Between 2002 and 2008, 1713 prospectively enrolled HCC patients were compared for their long-term survival by using the Akaike information criterion (AIC) according to the staging or scoring methods of these 5 models.
RESULTS: The mean and median follow-up duration was 18 and 14 months, respectively. Among all patients, the CLIP staging system had the lowest AIC value in comparison with other systems in the Cox proportional hazards model, followed by the Tokyo score, JIS score, BCLC staging system, and TNM staging system. Patients undergoing curative treatment had a significantly better survival in comparison with patients undergoing noncurative treatment (P < .001). When the predictive accuracy of the staging systems was analyzed according to treatment strategy, the CLIP staging system had the lowest AIC value and remained the best prognostic model in patients undergoing curative (801 patients) and noncurative (912 patients) treatment.
CONCLUSIONS: The CLIP staging system is the best long-term prognostic model for HCC in a cohort of patient with early to advanced stage of HCC. Its predictive accuracy is independent of the treatment strategy. Selecting an optimal staging system is helpful in improving the design of future clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20564406     DOI: 10.1002/cncr.25044

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  48 in total

Review 1.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

4.  Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.

Authors:  Wei-Fan Hsu; Po-Heng Chuang; Cheng-Kuo Chen; Hung-Wei Wang; Ming-Hung Tsai; Wen-Pang Su; Hung-Yao Chen; Chi-Ying Yang; Chun-Che Lin; Guan-Tarn Huang; Jaw-Town Lin; Hsueh-Chou Lai; Cheng-Yuan Peng
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

5.  Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.

Authors:  Jong Kwan Kim; Hyung-Don Kim; Mi-Jung Jun; Sung-Cheol Yun; Ju Hyun Shim; Han Chu Lee; Danbi Lee; Jihyun An; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee; Kang Mo Kim
Journal:  Dig Dis Sci       Date:  2017-08-16       Impact factor: 3.199

6.  I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Authors:  Ahmed O Kaseb; James L Abbruzzese; Jean-Nicolas Vauthey; Thomas A Aloia; Eddie K Abdalla; Manal M Hassan; E Lin; Lianchun Xiao; Adel S El-Deeb; Asif Rashid; Jeffrey S Morris
Journal:  Oncology       Date:  2011-08-03       Impact factor: 2.935

Review 7.  Treatment of hepatocellular carcinoma: a systematic review.

Authors:  Shibo Lin; Katrin Hoffmann; Peter Schemmer
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 8.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

9.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

Review 10.  Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Dong Soo Lee; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-03       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.